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Abstract We describe a new type of cardiomyopathy caused
by a mutation in the glycogenin-1 gene (GYG1). Three unre-
lated male patients aged 34 to 52 years with cardiomyopathy
and abnormal glycogen storage on endomyocardial biopsy
were homozygous for the missense mutation p.Asp102His
in GYG1. The mutated glycogenin-1 protein was expressed
in cardiac tissue but had lost its ability to autoglucosylate as
demonstrated by an in vitro assay and western blot analysis. It
was therefore unable to form the primer for normal glycogen
synthesis. Two of the patients showed similar patterns of heart
dilatation, reduced ejection fraction and extensive late gado-
linium enhancement on cardiac magnetic resonance imaging.
These two patients were severely affected, necessitating car-
diac transplantation. The cardiomyocyte storage material was
characterized by large inclusions of periodic acid and Schiff
positive material that was partly resistant to alpha-amylase
Communicated by: Sylvia Stoeckler-Ipsiroglu
Electronic supplementary material The online version of this article
(doi:10.1007/s10545-016-9978-1) contains supplementary material,
which is available to authorized users.
* Anders Oldfors
anders.oldfors@gu.se
Carola Hedberg-Oldfors
carola.oldfors@gu.se
Emma Glamuzina
EGlamuzina@adhb.govt.nz
Peter Ruygrok
PRuygrok@adhb.govt.nz
Lisa J. Anderson
Lisa.Anderson@stgeorges.nhs.uk
Perry Elliott
perry.elliott@ucl.ac.uk
Oliver Watkinson
oliver.watkinson@nhs.net
Chris Occleshaw
ChrisO@adhb.govt.nz
Malcolm Abernathy
Malcolma@whc.co.nz
Clinton Turner
ClintonT@adhb.govt.nz
Nicola Kingston
NKingston@adhb.govt.nz
Elaine Murphy
elaine.murphy@uclh.nhs.uk
1 Department of Pathology and Genetics, University of Gothenburg,
Gothenburg, Sweden
2 National Metabolic Service, Starship Children’s Hospital,
Auckland, New Zealand
3 Green Lane Cardiovascular Service, Auckland City Hospital,
Auckland, New Zealand
4 Department of Cardiology, St George’s Hospital, London, UK
5 Barts Heart Centre, London, UK
6 Wakefield Heart Centre, Wakefield Hospital, Wellington, New
Zealand
7 Anatomical Pathology, LabPlus, Auckland City Hospital,
Auckland, New Zealand
8 Charles Dent Metabolic Unit, National Hospital for Neurology and
Neurosurgery, London, UK
J Inherit Metab Dis (2017) 40:139–149
DOI 10.1007/s10545-016-9978-1
treatment consistent with polyglucosan. The storage material
had, unlike normal glycogen, a partly fibrillar structure by
electron microscopy. None of the patients showed signs or
symptoms of muscle weakness but a skeletal muscle biopsy
in one case revealed muscle fibres with abnormal glycogen
storage. Glycogenin-1 deficiency is known as a rare cause of
skeletal muscle glycogen storage disease, usually without car-
diomyopathy. We demonstrate that it may also be the cause of
severe cardiomyopathy and cardiac failure without skeletal
muscle weakness. GYG1 should be included in cardiomyop-
athy gene panels.
Introduction
Glycogen storage diseases (GSD) are important causes of
myopathy and cardiomyopathy and are in most instances
the consequence of a deficiency of an enzyme involved in
glycogen metabolism. There are two types of muscle
glycogenoses, those with defective degradation of normal
glycogen (such as GSD II, III, V, VII, IX) and those with
defective synthesis of glycogen (GSD 0, IV, XV)
(DiMauro and Spiegel 2011; Oldfors and DiMauro 2013;
Hedberg-Oldfors and Oldfors 2015).
Muscle GSD associated with deficiency of enzymes
involved in glycogen synthesis include glycogen synthase
(GYS1; GSD 0), branching enzyme (GBE1; GSD IV) and
glycogenin-1 (GYG1; GSD XV). Glycogenin-1 is an
autoglucosylating enzyme serving as a primer for glyco-
gen synthase and branching enzyme by the formation of
an oligosaccharide consisting of 8–14 glucose molecules,
which is bound to glycogenin-1 by a glucose-O-tyrosyl
linkage at position 195 (Lomako et al 2004; Roach et al
2012). Previously described individuals with GSD XV
had pure myopathy except one patient who also had car-
diac involvement with arrhythmias (Moslemi et al 2010;
Malfatti et al 2014; Colombo et al 2016; Fanin et al 2015;
Luo et al 2015; Akman et al 2016).
We describe three patients with cardiomyopathy and heart
failure necessitating cardiac transplantation in two.
Investigations revealed massive storage of abnormal glycogen
in the heart and a homozygous missense mutation in GYG1
resulting in a nonfunctional glycogenin-1 in all patients.
Patients and methods
A summary of the results from clinical, radiological and lab-
oratory examinations are presented in Table 1. The study com-
plies with the Declaration of Helsinki and informed consent
has been obtained from the patients.
Patient 1
This 49-year-old man was of New Zealand-British descent.
He presented to cardiac services at 36 years of age with pal-
pitations and exertional chest pain. For approximately 2 years
prior he had episodes of calf pain, with increasing shortness of
breath on exertion and lethargy. He had previously been very
active. He had normal intellect, no history of recorded
hypoglycaemia or symptoms to suggest this, a normal birth
and childhood and no other medical problems. His mother and
father died in their 70s of a cerebrovascular accident and bow-
el cancer respectively. He has an older brother and sister and
two sons, all of whom are well. His echocardiogram at pre-
sentation revealed severe cardiac hypertrophy with speckling
of the cardiac muscle and an ejection fraction of 44 %. A
cardiac muscle biopsy was performed and glycogen accumu-
lation was seen (see below).
He had no clinical evidence of skeletal muscle disease or
weakness, but a mildly elevated serum creatine kinase (s-CK)
on one occasion. Muscle biopsy showed an abnormal glyco-
gen pattern (see below) and a liver biopsy showed
microvesicular steatosis and glycogen accumulation with mild
inflammation. He had no hepatomegaly and his liver enzyme
tests and liver ultrasound scans were normal.
He progressed to develop increasing fatigue and lethargy,
worsening cardiac hypertrophy with secondary dilatation and
worsening ejection fraction (28% at 44 years). At age 45 years
a cardiac MRI (Fig. 1a-e) demonstrated a severely dilated left
ventricle with moderate-severely impaired ventricular func-
tion. Right ventricular function was normal without any focal
thickening or hypertrophy. Regional wall motion assessment
showed a complex pattern of akinesis. There was delayed
gadolinium enhancement showing an extensive pattern of
scarring with a patchy appearance, mostly in the mid-
myocardial or sub-epicardial segments. The myocardium
was thinned out in the posterolateral wall with almost full
thickness scarring. Coronary angiogram at 45 years was
normal.
He developed increasing issues with cardiac arrhythmia
and an ICD was implanted. He had many episodes of anti-
tachycardia pacing and three shocks.
He was listed for cardiac transplantation at 48 years of age
and underwent a cadaveric donor transplant 1 month later. He
had no significant complications and no clinical evidence of
multi-system disease at the last examination 6 months post
transplantation.
Patient 2
This 52-year-old man presented at age 46 years with left-sided
weakness, 2 days after a boating accident. He had a back-
ground history of hypertension and dyslipidemia. A right mid-
dle cerebral artery infarct was diagnosed. He was treated with
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thrombolysis and made a good recovery. An echocardiogram
at the time showed a thickened interventricular septum
(1.3 cm), a mildly dilated left ventricle, and impaired systolic
function with an estimated ejection fraction of 40–50 %.
He had a normal birth and childhood. There were no other
specific medical issues. The family is non-consanguineous of
English background. He has three siblings—an elder brother
in his 50s with type 2 diabetes and two younger sisters, in their
40s. None of his siblings have known cardiac disease. A pa-
ternal grandfather died from a myocardial infarction aged
63 years. A paternal aunt had a valve replacement. There is
no other cardiac history within the family.
He remained well until aged 50 years when he developed
palpitations, sweatiness and chest pain whilst driving. He was
found to have ventricular tachycardia with presyncope and
ECG showed sinus rhythmwith markedly poor lateral R wave
progression (Fig. 1g). An echocardiogram showed severe left
ventricular dilatation. Systolic function was severely impaired
with an estimated ejection fraction of 30–35 %. There was
akinesis of the inferolateral wall and apical lateral wall and
hypokinesis of the anterolateral and anterior wall. There was
severe left ventricular diastolic dysfunction and moderate left
atrial dilatation with mild mitral regurgitation. Cardiac MRI
(Fig. 1h) confirmed that the left ventricle was severely dilated
Table 1 Results of clinical, radiological and laboratory examinations
Patient 1 Patient 2 Patient 3
Gender Male Male Male
Descent New Zealand/British British British
Age, years 49 52 34
Age of onset, years 34 46/50 23
Initial symptoms Shortness of breath, chest pain on
exertion, lethargy and palpitations
CVA/Chest pain, sweatiness and
palpitations
Shortness of breath and chest pain
ICD Age 45 years Age 49 years Age 31 years
Cardiac MRI (with gadolinium) Severely impaired left ventricular
function with severe dilatation.
Thinned out myocardium in the
posterolateral wall showing
almost full thickness scarring.
Diffusely patchy scarring mostly
in the epicardial and mid-
myocardial regions.
Severely dilated LVwith a large area
of thinning and akinesis affecting
the entire lateral wall from base to
apex (anterolateral, anterior and
inferolateral walls). Other regions
were hypertrophied with
preserved systolic function.
Extensive late gadolinium
enhancement in the entire thinned
region.
Very extensive (>50 %) late
gadolinium enhancement in a
non-ischaemic pattern. Moderate
LV impairment. Maximum LV
wall thickness of 23 mm.
ECG (before ICD insertion) Sinus rhythm. Widespread T wave
inversion. QRS duration 120 ms
Sinus rhythm with poor lateral R
wave progression. QRS duration
126 ms. QTc normal.
T wave inversion in leads I, II, III,
AVF and V6 with ST elevation in
leads V3-V6. QRS duration
102 ms. QTc normal.
Echocardiogram Age 48 years Age 50 years Age 32 years
Left ventricular end-diastolic
volume (ml)
281 277 151
Septal wall thickness (cm) 1,4 1,6 1,6
Posterior wall thickness (cm) 0,9 1,0 1,4
Ejection fraction (%) 25–30 30–35 59
Coronary angiogram Normal Normal Normal
Heart transplantation Age 48 years Age 52 years No
Endomyocardial biopsy
Light microscopy
PAS-positive inclusions partial
removal by diastase
PAS-positive inclusions partial
removal by diastase
PAS-positive inclusions
Electron microscopy Normal glycogen and filamentous or
amorphous material
Not performed Storage of non-lysosomal glycogen
Muscle biopsy Variability of fibre size and scattered
fibres with accumulation of PAS-
positive inclusions
Not performed Not performed
Skeletal muscle strength Normal Normal Normal
GYG1 mutation Homozygous
c.304G>C, p.(Asp102His)
Homozygous
c.304G>C, p.(Asp102His)
Homozygous
c.304G>C, p.(Asp102His)
ICD Implantable cardioverter-defibrillator, CVA Cerebral vascular accident, MRI Magnetic resonance imaging, LV Left ventricle, ECG
Electrocardiography, PAS Periodic acid-Schiff
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with a large area of thinning and akinesis affecting the entire
lateral wall from base to apex (anterolateral, anterior and
inferolateral walls). Other regions were hypertrophied with
preserved systolic function. Late enhancement following gad-
olinium contrast was seen in the entire thinned region.
On examination, his weight was 81.2 kg. He did not have
palpable hepatomegaly. Skeletal muscle strength was normal.
An EMG was also normal. Blood glucose and lactate levels
were normal. Blood film showed no vacuolation or increase in
lymphocyte glycogen content. Red blood cell glycogen level
was also normal at 22ug/g Hb (RR: 10–120). An acylcarnitine
profile was normal. Creatine kinase was 88 IU/L (RR: 38–
204). No urinary glucose tetrasaccharide was detected.
The patient remained symptomatic with shortness of breath
on exertion. An ICD was inserted aged 49 years and a left
ventricular assist device aged 51 years. Orthotopic cardiac
transplant was performed aged 52 years. Initial post-
operative course was complicated by renal impairment requir-
ing haemofiltration. He is now well 6 months post-transplant.
Patient 3
This 34-year-old man of white UK background first presented
aged 23 years with shortness of breath and chest pain. Prior to
this he had been well, with active participation in cross-
country running and competitive football. A diagnosis of hy-
pertrophic cardiomyopathy was made. An ICD was fitted
aged 31 years and current medications include bisoprolol,
spironolactone and warfarin. He has never had skeletal muscle
weakness or symptoms suggestive of hypoglycaemia.
He reported a normal birth and childhood. He has two
siblings, a brother aged 39 years has been screened by
Fig. 1 Cardiac MRI (A-E) and explant (F) of patient 1, ECG (G) and
cardiac MRI (H) of patient 2 and cardiac MRI (I) of patient 3. a A 2-
chamber vertical long-axis delayed enhancement image of the LV
demonstrating very extensive increased signal in the inferior surface,
the distal half of the diagonal surface, and the LV apex, predominantly
in the mid-myocardial and subepicardial layers of the myocardium. The
abnormal signal indicates the presence of fibrosis or scar tissue. b A 4-
chamber long-axis delayed enhancement image of the LV, demonstrating
extensive abnormal enhancement consistent with fibrosis or scar
formation in the mid-myocardial and subepicardial layers of the
myocardium, involving the entire obtuse marginal surface, the apex and
the posterior ventricular septum. c A 2-chamber vertical long-axis cine
frame of the LV at end-diastole, which is dilated and globular in shape.
There is variable wall thickness, with thinning of the distal half of the
diagonal surface and the apex. An increased number of trabeculations in
these regions indicates localized non-compaction of the myocardium. dA
short-axis cine frame of the middle third of the LVat end-diastole shows
thinning of the obtuse marginal surface, with markedly increased
trabeculation of both this region, and, albeit to a lesser extent, of the
diagonal and anterior septal myocardium also. e A short-axis cine frame
of the basal LV at end-systole demonstrates variable increase in wall
thickening in the ventricular septum and diagonal surfaces, with marked
wall thinning in the posterior obtuse marginal and inferior surfaces. f
Transverse section of the explanted heart including the right ventricle
interventricular septum and parts or the left ventricle demonstrating
variable thickening of the septum and thin and trabeculated posterior
wall (arrow). g ECG of patient 2 demonstrating sinus rhythm with very
poor R wave progression in the lateral leads. h Cardiac MRI of patient 2
demonstrating a markedly dilated left ventricle with thin lateral wall with
late gadolinium contrast enhancement. i Cardiac MRI of patient 3
demonstrating extensive late gadolinium contrast enhancement
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echocardiography and has no cardiac disease, a sister aged
29 years has opted not to be screened. Both siblings are clin-
ically well. A maternal uncle has hypertrophic cardiomyopa-
thy of unknown cause (no endocardial biopsy or genetic stud-
ies performed).
On examination, he had no hepatomegaly and muscle
strength was normal. ECG, echocardiogram and cardiac
MRI findings were as in Table 1 and demonstrated hypertro-
phic cardiomyopathy with moderate to severe LVH, mild
RVH and marked late gadolinium enhancement (Fig. 1i).
Blood glucose and lactate levels were normal. Creatine
kinase was 189 IU/L (RR: 38–204). Red blood cell glycogen
level was normal at 22 μg/g Hb (RR: 10–120). Excess urinary
glucose tetrasaccharide was not detected.
Morphological and immunohistochemical analysis
Endomyocardial biopsy from the right ventricle was per-
formed at the age of 48 years (patient 1), 49 years (patient 2)
and 33 years (patient 3). The specimens were fixed in parafor-
maldehyde for paraffin embedding or glutaraldehyde for elec-
tron microscopy. Open skeletal muscle biopsy of the quadri-
ceps muscle was performed at the age of 37 years (patient 1).
Specimens were snap frozen for cryostat sectioning and his-
tochemistry. Standard techniques were applied for histochem-
ical staining.
Molecular genetic analysis
DNA from all three patients was analysed by sequencing a
panel of genes associated with muscle glycogen storage dis-
eases (AGL; ALDOA; ENO3; FBP2; GAA; GBE1; GYG1;
GYS1; LDHA; PFKM; PGAM2; PGK1; PHKA1; PHKG1;
PYGM) (Sheffield Diagnostics Genetics Service, UK).
Patients 2 and 3 also had mutation analysis of the LAMP2
and PRKAG2 genes prior to the panel sequencing but no path-
ogenic variants were detected. Patient 3 in addition had a
cardiomyopathy gene panel investigation including 40 genes
but only aMYH6 variant of uncertain importance was detected
(Sheffield Diagnostics Genetics Service, UK). This variant
was also detected in his asymptomatic mother.
Whole-exome sequencing
Whole-exome sequencing (WES) was performed in all three
patients. Target enrichment was performed with 0.5 μg of
genomic DNA using the Sure SelectXT Human All Exon kit
version 6 (Agilent Technologies, Santa Clara, CA, USA) and
sequenced on the HiSeq2500 platform (Illumina, San Diego,
CA, USA) as paired-end 125-bp reads with 60× coverage.
Base calling was performed with the Illumina pipeline, with
default parameters. Sequence reads were aligned to the refer-
ence genome (hg19) using Burrows-Wheeler Aligner (BWA).
Variant calling was performed with DNAnexus software
(DNAnexus Inc., Mountain View, CA; www.dnanexus.
com). Filtering of called variants was performed in several
steps using Ingenuity Variant Analysis (www.ingenuity.
com/products/variant-analysis). We analysed 65 genes
associated with cardiomyopathy (genes available on
request). Further filtering was done to predict pathogenic
variants using SIFT and PolyPhen2, the level of
conservation and how common the variants are in the
population (using 1000 Genome (http://www.1000genomes.
org/); NHLBI Exome Sequencing Project (ESP) (http://evs.gs.
washington.edu/EVS/); The Exome Aggregation Consortium
(ExAC, http://exac.broadinstitute.org/)) to reduce the number
of variants.
Protein expression—western blot
Western blot was performed on protein extract from cryostat
sections of a cardiac muscle biopsy specimen from patient 1,
with or without alpha-amylase treatment. The alpha-amylase
treatment was performed by incubating the cryostat section
with 10 μg/ml human alpha-amylase (Sigma-Aldrich, St
Louis, MO) in a total volume of 10 μl phosphate-buffered
saline, pH 6.5 for 1 h at 37 °C. The protein extractions were
performed by denaturing the samples using Laemmli sample
buffer with 5 % β-mercaptoethanol, incubating 4 min at 95 °C
and a final centrifugation for 10 min. The supernatants includ-
ing protein were loaded and separated on 10 % Bis-Tris gel
(Novex; Life Technologies, Grand Island, NY) followed by
electroblotting. The membranes were incubated with primary
antihuman glycogenin-1 N-terminal antibody M07 clone 3B5
(Abnova, Taipei, Taiwan; 1:500). Western Breeze
Chromogenic kit (Life Technologies) was used for antibody
detection.
Cell-free glycogenin-1 expression and in vitro
glucosylation
A cell-free protein expression system was used to analyse the
autoglucosylation ability of the mutant protein. Site-directed
mutagenesis of the glycogenin-1 sequence (NM_001184720)
inserted in a pEXP5-NT/TOPO vector (Life Technologies,
Carlsbad, CA) was performed using the QuikChange II site-
directed mutagenesis protocol (Agilent Technologies, Santa
Clara, CA, USA). Sanger sequencing confirmed the correct
sequence. The FastLane Escherichia coli protein synthesis kit
(RiNA, Berlin Germany) was used to express the mutated and
wild type glycogenin-1 according to the manufacturer’s pro-
tocol. The expressed glycogenin-1 proteins were allowed to
autoglucosylate in N-2-hydroxyethylpiperazine-N-2-
ethanesulfonic acid (50 mM, pH7.5), MnCl2 (5 mM), dithio-
threitol (0.5 mM) and 0.1 M uridine diphosphate (UDP)-glu-
cose (Calbiochem, San Diego, CA) for 1 h at 30 °C (Hurley
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et al 2005). Half of the protein extract was treated with
10 μg/ml human alpha-amylase (Sigma-Aldrich, St Louis,
MO) for 1 h at 37 °C. Western blot was performed on the
protein extract with or without alpha-amylase treatment, de-
natured using Laemmli sample buffer with 5 % β-
mercaptoethanol and separated on a 10 % Bis-Tris gel
(Novex, Life Technologies, Grand Island, NY) followed by
electroblotting. The membrane was incubated with primary
antihuman glycogenin-1 N-terminal antibody M07 clone
3B5 (Abnova, Taipei, Taiwan; 1:500). Western Breeze
Chromogenic kit (Life Technologies) was used for antibody
detection.
Results
Morphological investigations
Endomyocardial biopsy of patient 1 showed storage of peri-
odic acid-Schiff (PAS) positive material that was partially re-
sistant to digestion by alpha-amylase in most cardiomyocytes
(Fig. 2a-c). By electron microscopy this material appeared as
normal glycogen but in many regions it was composed of
filamentous or amorphous material (Fig. 2d-e). Skeletal mus-
cle biopsy demonstrated variability of muscle fibre size and
scattered muscle fibres with accumulation of PAS positive
material. These fibres were frequently but not consistently
devoid of normal glycogen (Fig. 2f).
In patient 2 an endomyocardial biopsy showed abnormal
hypertrophied myocytes with extensive vacuolation replacing
most of the cell (Suppl. Fig. 1). There was no evidence of
inflammation, no vasculitis and no abnormal infiltrates.
PAS-staining was positive with partial removal by diastase.
Electron microscopy was not done.
Similarly, an endomyocardial biopsy from patient 3
showed myocyte enlargement with irregular hyperchromatic
nuclei (Suppl. Fig. 2a, b). There was marked cytoplasmic
vacuolation. PAS-staining was positive. Mitochondria were
of normal size and morphology and were displaced by glyco-
gen. Electron microscopy confirmed the storage of non-
lysosomal glycogen, with displacement of nuclei and mito-
chondria (Suppl. Fig. 2c).
Molecular genetic analysis
All three patients (Fig. 3a) were homozygous for a
c.304G > C, p.Asp102His mutation in exon 3 of the GYG1
gene (NM_004130.3) (Fig. 3b, c). The substitution of a neg-
atively charged aspartic acid with a positively charged histi-
dine was predicted to be highly pathogenic both by PolyPhen-
2 with a score of 1.00 and SIFT function prediction.
The affected amino acid is in a highly conserved position
among species with a conservation phyloP p-value of 1.000E-
6. This variant is detected in 0.13% in NHLBI ESP and with a
1000 Genomes frequency of 0.04 %.
Sixty-five candidate genes associatedwith cardiomyopathy
were screened in all three patients. Most called variants after
Fig. 2 Endomyocardial and skeletal muscle biopsy of patient 1 with
abnormal glycogen storage; (a) in virtually every cardiomyocyte there
is a large central region with storage material (arrows; hematoxylin and
eosin); (b) the storage material is intensely positive in PAS staining; (c) it
is to a minor degree resistant to alpha-amylase treatment; (d) electron
microscopy demonstrating accumulation of glycogen with normal
appearance (arrow-head) as well as paler regions with storage of other
type of material (arrow) that at higher magnification (e, inset in Fig. 1d)
has a fibrillar (arrows) or unstructured (arrow-head) appearance. There is
also some normal glycogen particles in addition to mitochondria and
lipofuscin in this image; (f) skeletal muscle biopsy demonstrating by
PAS staining that some fibres that look pale show accumulation of PAS
positivematerial (arrows). There are also PAS positive inclusions in fibres
with normal glycogen content (arrow-head)
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filtering were predicted to be likely benign or with uncertain
significance according to computed ACMG Guidelines clas-
sification. Only a MYH6 variant of uncertain importance was
detected in patient 3. This variant was also detected in his
asymptomatic mother. The only clearly pathogenic variant
was the homozygous GYG1 c.304G > C mutation in all three
patients.
Genetic testing of family members revealed that the sister
of patient 1 was also homozygous for the GYG1 c.304G > C
mutation. She was 53 years of age and had no clinical symp-
toms. Her ECG and echocardiogram were within normal
limits, and MRI was essentially normal with no evidence of
any abnormal signal on the delayed enhancement images.
Neither of the two sisters of patient 2 had known cardiac
disease. One was heterozygous for the c.304G > C allele and
the other had normalGYG1 sequence. The mother of patient 3
was heterozygous for the c.304G > C allele. No other family
members agreed to genetic testing.
Protein expression—western blot
In patient 1 the expression of glycogenin-1 in cardiac muscle
tissue was studied by western blot analysis either without or
with alpha-amylase treatment, to cleave off the glucose in the
glycogen particles (Fig. 3d). In normal individuals, there is no,
or very little, free glycogenin-1, since it is part of glycogen
particles and therefore it can only be detected by western blot
analysis after alpha-amylase treatment. In contrast,
glycogenin-1 was detected both with and without alpha-
amylase treatment in the patient demonstrating that it was
not glucosylated.
Fig. 2 Genetic and protein analysis. a Pedigrees of the families. b
Chromatogram of normal GYG1 DNA sequence with the DxD motif
indicated by hatched line. c Chromatogram demonstrating a
homozygous missense mutation in GYG1 (c.304G > C, p.Asp102His),
the hatched line shows that the DxD motif is mutated. d Western blot
analysis of glycogenin-1 on protein extracted from cardiac muscle biopsy
specimen from patient 1 and a control sample performed without (−) or
with alpha-amylase (+) treatment. In patient 1 glycogenin-1 was detected
both without and with alpha-amylase treatment compared to control
sample where glycogenin-1 was only detected after alpha-amylase treat-
ment. The band corresponding to myosin heavy chain was used as
loading control. e Cell-free autoglycosylation in vitro revealed that the
protein with the mutation p.Asp102His was not able to autoglycosylate
demonstrated with only one band after addition of uridine diphoshate
(UDP) glucose (+) compared to wild type (WT) protein which was able
to autoglycosylate demonstrated with two bands corresponding to both
unglucosylated (lower band) and glycosylated (upper band) glycogenin-
1. Unglucosylated glycogenin-1 weighs approximately 1 kDa less than
free autoglucosylated protein. After alpha-amylase treatment the short
glucose polymers are cleaved off resulting in only one band for WT
compared to p.Asp102His which was not affected because of absence
formation of short glucose polymers
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Cell-free expression and in vitro glucosylation
A normal gel shift, of approximately 1 kD after addition of
UDP-glucose, was demonstrated for wild type glycogenin-1,
indicating that it was autoglucosylated (Fig. 3e). Alpha-
amylase treatment of the recombinant autoglucosylated wild
type glycogenin-1 resulted in a reduction of the molecular
weight, further confirming that the observed gel shift was
due to autoglucosylation by the addition of 8–14 glucose res-
idues. The in vitro autoglucosylation assay for the glycogenin-
1 variant p.Asp102His did not demonstrate this expected gel
shift, indicating that it had lost the ability to autoglucosylate.
Discussion
Muscle GSD XV that is caused by variants in GYG1 belongs
to a group of disorders of glycogen metabolism with storage
of polyglucosan in muscle and other tissues (Hedberg-Oldfors
and Oldfors 2015). Several human genes are known to be
associated with polyglucosan storage in muscle including
GYG1, GBE1, RBCK1 (HOIL-1), PFKM, EPM2A, EPM2B
(NHLRC1), PRDM8 and PRKAG2. Two of these genes,
GYG1 and GBE1 encode for enzymes involved in glycogen
synthesis. Neuromuscular forms of branching enzyme
(GBE1) deficiency presents in many different clinical variants
the most severe being fetal akinesia deformation sequence
(FADS) but may also present with milder phenotypes with
onset in childhood or adulthood (Oldfors and DiMauro
2013). The classic presentation is characterized by progressive
liver cirrhosis leading to death in childhood unless liver trans-
plantation is performed. So-called adult polyglucosan body
disease manifests as a neurologic disorder with onset at 40–
60 years of age with neurogenic bladder, peripheral neuropa-
thy and central nervous system involvement causing spastic
gate and frequently cognitive impairment (Mochel et al 2012).
In branching enzyme deficiency there is polyglucosan accu-
mulated in the affected organs and tissues. RBCK1 deficiency
is a rare disease that is characterized by onset usually in child-
hood or adolescence of muscle weakness and rapidly progres-
sive cardiomyopathy (Nilsson et al 2013). Some patients may
also have immunodeficiency and autoinflammation (Boisson
et al 2012). Polyglucosan is accumulated in several tissues
including skeletal and cardiac muscle. Lafora disease is a le-
thal neurodegenerative disorder affecting adolescents
(Minassian 2001). It is characterized by intractable myoclonic
seizures, ataxia, visual hallucinations, cognitive decline and
later dementia. Lafora bodies that are composed of
polyglucosan are found in nerve cells and also in muscle.
Two genes are associated with Lafora disease; EPM2A
(laforin) and EPM2B (malin) and a third gene PRDM8 that
is associated with an early onset variant of Lafora body dis-
ease has been described (Turnbull et al 2012). In addition to
these disorders muscle phosphofructokinase (PFKM) and
AMP-activated protein kinase (PRKAG2) deficiency are
associated with occasional polyglucosan inclusions in
skeletal and cardiac muscle respectively (Arad et al 2005;
Malfatti et al 2012).
The pathogenesis of polyglucosan accumulation in muscle
is not completely known but is probably different in the var-
ious polyglucosan body diseases. In Lafora disease there is
evidence that lack of laforin, which functions to remove phos-
phate from glycogen, or deficient removal of laforin from
glycogen by malin makes the glycogen prone to aggregation
as polyglucosan (Tiberia et al 2012). An imbalance of the
activities of branching enzyme and glycogen synthase has
been proposed as important for polyglucosan formation in
equine polysaccharide storage myopathy (PSSM1) that is
due to hyper-activity of glycogen synthase (GYS1) secondary
to a dominant missense variant (McCue et al 2008).
We describe three unrelated patients homozygous for a
missense mutation in the GYG1 gene, presenting with glyco-
gen storage cardiomyopathy and heart failure in two of them.
There are several lines of evidence that the homozygous
c.304G > C mutation causes the disease. First, three unrelated
patients with the same homozygous mutation displayed a sim-
ilar cardiac phenotype. Second, the mutation alters a highly
conserved amino acid located in a motif essential for function.
Third, the mutation abolishes the normal autoglucosylation.
Fourth, a previously reported patient with other pathogenic
GYG1 mutations had similar abnormal glycogen storage in
the heart. Fifth, several other GYG1 mutations have been
shown to cause similar abnormal glycogen storage in skeletal
muscle. Sixth, whole-exome sequencing did not reveal any
pathogenic mutations in other genes associated with
cardiomyopathy.
This cardiomyopathy associated with a glycogenin-1 mu-
tation but without skeletal muscle weakness differs from the
previously described cases who typically had a rather late
onset skeletal myopathy without cardiomyopathy (Malfatti
et al 2014; Colombo et al 2016; Fanin et al 2015; Luo et al
2015; Akman et al 2016). Altogether 22 patients have been
diagnosed with GYG1 associated skeletal- or cardiomyopathy
(for details of 19 previously reported patients see Suppl.
Table 1). The majority of patients had adult onset (40–
65 years), slowly progressive myopathy with muscle weak-
ness that was predominantly proximal and symmetrical, caus-
ing walking difficulties with myopathic gait, difficulty in
climbing stairs and hyperlordosis. Some patients have become
wheelchair-dependent. In two patients there was a suspicion
of childhood onset. Exercise intolerance, myalgia and distal
muscle weakness were reported in a few patients. EMG was
myopathic with a neurogenic component in a few cases.
Serum-CK was mildly elevated in only five patients. In the
majority of patients, cardiac examination including echocar-
diography and ECG was normal. Muscle pathology showed
146 J Inherit Metab Dis (2017) 40:139–149
characteristic alterations, similar to patient 1 described in this
paper, with PAS positive inclusions in a proportion of the
muscle fibres that were depleted of normally distributed gly-
cogen. These PAS positive inclusions were partly resistant to
digestion by alpha-amylase. In addition, muscle tissue was
atrophic with muscle fibre size variability and increase in in-
terstitial fat and fibrous connective tissue. One patient had
depletion of glycogen alone, without inclusions. This patient
also had cardiomyopathy. To date, no impact on liver function
has been reported, and glycogen storage such as seen in the
biopsy from patient 1 may be subclinical. This may be due to
glycogenin-2 that is expressed in the liver, although the im-
portance of glycogenin-2 has been debated (Irgens et al 2015).
In previously described patients, at least 32 loss-of-function
(nonsense and splice site) variants in the 38GYG1 alleles were
identified. The most common variant is c.143 + 3G > C that
has been identified in 25 alleles.
The clinical variability of GYG1 mutations therefore seems
to include pure skeletal myopathy and pure cardiomyopathy
that may lead to cardiac failure. In addition, the first described
case with a glycogenin-1 associated glycogen storage disease
presented with cardiac arrest caused by arrhythmia (Moslemi
et al 2010). This patient had the same type of storage of abnor-
mal glycogen in cardiomyocytes as the cases presented in the
present report. However, he also had muscle weakness and
depletion of glycogen in skeletal muscle, which further
broadens the clinical spectrum. It is noteworthy that the sister
of patient 1, who is also homozygous for theGYG1 c.304G >C
mutation does not show signs or symptoms of cardiac or skel-
etal muscle disease. This is in line with the previously noted
great variability of clinical expression of even the same GYG1
mutation. The homozygous GYG1 c.143 + 3G> C mutation
showed variability of age at onset from childhood to age
60 years in 11 reported patients (Malfatti et al 2014; Colombo
et al 2016; Fanin et al 2015; Akman et al 2016).
Patients with glycogenin-1 deficiency and cardiomyopathy
demonstrated extensive late gadolinium enhancement by cardi-
ac MRI. This finding in addition to endomyocardial biopsy
demonstrating glycogen storage may be a clue to the correct
diagnosis, which can be verified by glycogenin-1 gene analysis.
In the future, the addition of GYG1 to cardiomyopathy gene
panels will simplify the identification of these patients.
Considering the relative high frequency of the GYG1
c.304G > C allele it may be anticipated that many more
glycogenin-1 associated cardiomyopathy patients will be iden-
tified. The mutation was identified in 16/8584 alleles in
European Americans in the NHLBI ESP (Exome Variant
Server, NHLBI GO Exome Sequencing Project (ESP),
Seattle, WA; URL: http://evs.gs.washington.edu/EVS/) (June,
2015) and in 95/66728 alleles in European Non Finnish popu-
lation in the ExAC database. All three patients were homozy-
gous for the c.304G >C, p.Asp102His mutation in exon 3 of
the GYG1 gene. All patients are of British descent so it may be
speculated that there is a founder mutation. Further analysis on
the segregation of haplotypes may clarify this issue.
The mutated glycogenin-1 protein was expressed in
cardiac muscle. The affected amino acid is in a highly
conserved position among species (Fig. 4a-b). It is located
in the DxD motif, which is essential for the coordination
of the catalytic divalent cation Mn2+ (Fig. 4c) (Gibbons
et al 2002). Glycogenin-1 folding creates a cleft for the
sugar-donor UDP-glucose and Mn2+ and the DxD is lo-
cated in the putative active site of the enzyme (Persson
et al 2001; Gibbons et al 2002).
Glycogenin-1 belongs to glycosyltransferase family 8,
which includes galactinol synthases, galactose transferases
and lipopolysaccharide glucose transferases (Campbell et al
1997). The DxD motif is well conserved and found in all
family 8 glycosyltransferases (Persson et al 2001).
Mutations of one of the Asp residues within the DxD motif
are described to result in inhibition of glycosyl transferase
activity in several different species (Busch et al 1998;
Shibayama et al 1998). Other glycosyltransferases with DxD
motifs that are involved in muscle diseases include
acetylglucosaminyltransferase-like protein (LARGE)
(Brock ington e t a l 2005) , a member of the N-
acetylglucosaminyltransferase gene family, B3GAT1 a Beta-
1,3-glucuronyltransferase (Mitsumoto et al 2000) and DPM1,
a member of the glycosyltransferase family 2 (Tomita et al
1998) (Fig. 4a).
In line with the predicted deleterious effect of the mutation,
our results from western blot analysis of protein extract from
cardiac tissue of patient 1 and the in vitro autoglucosylation
assay demonstrated loss of autoglucosylation caused by the
p.Asp102His GYG1 mutation. In cardiac tissue glycogenin-1
was detected both without and with alpha-amylase treatment
in protein extract from patient 1 compared to control sample
where glycogenin-1 was only detected after alpha-amylase
treatment, thus demonstrating that it did not initiate glycogen
synthesis in the patient. This was confirmed by the in vitro
autoglycosylation assay, which demonstrated that the
autoglycosylation activity was abolished by the replacement
of Asp at position 102 with His.
The expression of a non-functional glycogenin-1 was also
described in a previous case with cardiomyopathy (Moslemi
et al 2010). Analysis of glycogenin-1 expression has been per-
formed in only a few cases with isolated skeletal muscle weak-
ness. In a series of five patients with skeletal myopathy reported
by Malfatti et al (2014) there was either a markedly reduced
amount or complete absence of glycogenin-1 protein in skeletal
muscle. This may indicate that high expression of a non-
functional mutated protein might be more deleterious to the
heart than absence of the glycogenin-1 protein. One previously
reported patient with clinically pure skeletal myopathy was
compound heterozygous for the p.Asp102His GYG1 mutation
and a nonsense variant but no western blot was performed so it
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is not known to what extent themutant protein was expressed in
that case (Malfatti et al 2014). Although our patients with car-
diomyopathy had no muscle weakness, a biopsy of patient 1
demonstrated involvement of skeletal muscle. Thus, there may
be a combined sub-clinical involvement only disclosed by a
biopsy, which may be of diagnostic value in some cases.
The accumulation of apparently normal as well as abnor-
mal glycogen forming amorphous or fibrillar material in the
myocardium is intriguing in view of the abolished glycogenin-
1 activity. The accumulated glycogen is partly alpha-amylase
resistant and has a partly filamentous structure compatible
with amylopectin-like material or polyglucosan. This type of
storage in muscle is not unique for glycogenin-1 deficiency
but is also found in deficiency of branching enzyme, phospho-
fructokinase and RBCK1 and in Lafora disease among others
(Hedberg-Oldfors and Oldfors 2015). Therefore, multiple dif-
ferent gene mutations result in this type of abnormal storage.
Future studies on the detailed composition of the storage ma-
terial in these diseases may unravel the pathogenesis.
The cause of cardiomyopathy and cardiac failure in
glycogenin-1 deficiency is not fully understood but cellular
overload of storage material leading to cell death and secondary
fibrosis as demonstrated byMRI and histological investigations
is a plausible explanation. A cytotoxic effect of storage material
in addition to depletion of normal glycogen could be of impor-
tance for the pathophysiology both in skeletal and cardiac mus-
cle. Unlike some other metabolic disorders, e.g. Pompe disease
(GSD II) enzyme replacement therapy is at present not available
in glycogenin-1 deficiency. Although there are no reports of
dietary management for glycogenin-1 defects, triheptanoin (a
seven-carbon triglyceride) is currently in clinical trials for other
glycogen storage (GDS V, NCT02432768) and polyglucosan
body (GSD IV, NCT00947960) disorders and so may have a
potential future role in management. Further research on the
pathogenic mechanism may identify goals for specific thera-
peutic interventions.
In conclusion we have identified three unrelated patients
homozygous for a missense GYG1 mutation presenting with
Fig. 4 The glycogenin-1 protein. a Alignment of glycogenin-1 proteins
in different species. The bottom three lines demonstrating proteins
belonging to other gene families with DxD motif. The amino acid
affected by the mutation in red and within the hatched line is the
conserved DxD motif. b Illustration of the stereo view of glycogenin-1
with the amino acids in the DxD motif marked with colours, the affected
aspartic acid at position 102 in red, alanine and aspartic acid at positions
103 and 104 respectively in green. UDP-glucose is labelled in blue and
Mn2+ is labelled in purple. This figure was generated using The PyMOL
Molecular Graphics System, Version 1.7.2.1 Schrödinger, LLC. c
Schematic illustration of the interaction between glycogenin-1, UDP-
glucose and Mn2+. Amino acids within the DxD motif are included and
labelled in colours, the amino acid affected by mutation is in red
(modified from Gibbons et al 2002). d Higher magnification of the
stereo view demonstrating the UDP-glucose, Mn2+ and the DxD motif.
The polar contact between UDP-glucose and Asp102 is demonstrated
with the yellow-hatched line. The same colour scheme is used
throughout the figure
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cardiomyopathy and progressive dilatation and heart failure in
two of them, demonstrating that glycogenin-1 deficiency
should be considered a cause of cardiomyopathy in adults.
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